Integrating these features with patient-specific molecular and genetic profiles (e.g., IDH mutation status, MGMT promoter methylation, EGFR amplification, TERT promoter mutations) allows for non-invasive prediction of tumor biology, prognosis, and potential treatment response [68]. This evidence concerns the gene IDH1 and neoplasm.